PMID- 33228610
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 23
TI  - Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic 
      review and meta-analysis.
PG  - 174
LID - 10.1186/s12902-020-00653-x [doi]
LID - 174
AB  - BACKGROUND: We aimed to explore metabolite biomarkers that could be used to 
      identify pre-diabetes and type 2 diabetes mellitus (T2DM) using systematic review 
      and meta-analysis. METHODS: Four databases, the Cochrane Library, EMBASE, PubMed 
      and Scopus were selected. A random effect model and a fixed effect model were 
      applied to the results of forest plot analyses to determine the standardized mean 
      difference (SMD) and 95% confidence interval (95% CI) for each metabolite. The 
      SMD for every metabolite was then converted into an odds ratio to create an 
      metabolite biomarker profile. RESULTS: Twenty-four independent studies reported 
      data from 14,131 healthy individuals and 3499 patients with T2DM, and 14 included 
      studies reported 4844 healthy controls and a total of 2139 pre-diabetes patients. 
      In the serum and plasma of patients with T2DM, compared with the healthy 
      participants, the concentrations of valine, leucine, isoleucine, proline, 
      tyrosine, lysine and glutamate were higher and that of glycine was lower. The 
      concentrations of isoleucine, alanine, proline, glutamate, palmitic acid, 
      2-aminoadipic acid and lysine were higher and those of glycine, serine, and 
      citrulline were lower in prediabetic patients. Metabolite biomarkers of T2DM and 
      pre-diabetes revealed that the levels of alanine, glutamate and palmitic acid 
      (C16:0) were significantly different in T2DM and pre-diabetes. CONCLUSIONS: 
      Quantified multiple metabolite biomarkers may reflect the different status of 
      pre-diabetes and T2DM, and could provide an important reference for clinical 
      diagnosis and treatment of pre-diabetes and T2DM.
FAU - Long, Jianglan
AU  - Long J
AD  - Beijing Key Laboratory and Joint Laboratory for International Cooperation of 
      Bio-characteristic Profiling for Evaluation of Rational Drug Use, Capital Medical 
      University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, 611130, China.
FAU - Yang, Zhirui
AU  - Yang Z
AD  - Beijing Key Laboratory and Joint Laboratory for International Cooperation of 
      Bio-characteristic Profiling for Evaluation of Rational Drug Use, Capital Medical 
      University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China.
FAU - Wang, Long
AU  - Wang L
AD  - Department of Applied Mathematics and Statistics, Johns Hopkins University, 
      Baltimore, MD, 21218, USA.
FAU - Han, Yumei
AU  - Han Y
AD  - Beijing Physical Examination Center, Beijing, 100077, China.
FAU - Peng, Cheng
AU  - Peng C
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, 611130, China.
FAU - Yan, Can
AU  - Yan C
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. 
      Yanc020@126.com.
FAU - Yan, Dan
AU  - Yan D
AUID- ORCID: 0000-0002-1288-4144
AD  - Beijing Key Laboratory and Joint Laboratory for International Cooperation of 
      Bio-characteristic Profiling for Evaluation of Rational Drug Use, Capital Medical 
      University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. 
      pharmsci@126.com.
LA  - eng
GR  - 81773891/National Natural Science Foundation of China/
GR  - 2017ZX09301-040/the National Great New Drugs Development Project of China/
GR  - 2018000021223TD09, 2018-2-2242, 7194280/the Beijing Municipal Science and 
      Technology Commission/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201123
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/*metabolism
MH  - Diabetes Mellitus, Type 2/*diagnosis/metabolism
MH  - Humans
MH  - *Metabolome
MH  - Prediabetic State/*diagnosis/metabolism
MH  - Prognosis
PMC - PMC7685632
OTO - NOTNLM
OT  - Biomarker
OT  - Metabolite
OT  - Pre-diabetes; meta-analysis
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/25 06:00
MHDA- 2021/08/24 06:00
PMCR- 2020/11/23
CRDT- 2020/11/24 05:37
PHST- 2020/05/08 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/11/24 05:37 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/11/23 00:00 [pmc-release]
AID - 10.1186/s12902-020-00653-x [pii]
AID - 653 [pii]
AID - 10.1186/s12902-020-00653-x [doi]
PST - epublish
SO  - BMC Endocr Disord. 2020 Nov 23;20(1):174. doi: 10.1186/s12902-020-00653-x.